… two dosing cohorts and is intended to inform next steps in development. We also plan to provide an update from the … Rare Pediatric Disease designation from the Food and Drug Administration (FDA). Granted access to the PRIority … data from the study are expected in 2021. Received Orphan Drug designation and Fast Track designation from the FDA. …
QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
On behalf of all ProQRians, happy Rare Disease Day 2022. Both within ProQR and outside, we join the community in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, and supporters.
… ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands, March … Strategy Officer. Dr. Rodman has had a long career in drugdevelopment including leadership roles in translational …
